Indian Journal of Endocrine Surgery and Research

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  18 (2023)
Volume  17 (2022)
Volume  16 (2021)
Volume  15 (2020)
Volume  13 (2018)
Volume  12 (2016)
Volume  11 (2014)
Related articles

VOLUME 17 , ISSUE 1 ( January-June, 2022 ) > List of Articles

REVIEW ARTICLE

The Panorama of Hyperparathyroidism

Gopal Puri, Chitresh Kumar

Keywords : Hypercalcemia, Hyperparathyroidism, Primary hyperparathyroidism

Citation Information : Puri G, Kumar C. The Panorama of Hyperparathyroidism. 2022; 17 (1):40-51.

DOI: 10.5005/jp-journals-10088-11184

License: CC BY-NC 4.0

Published Online: 28-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Hyperparathyroidism occurs due to increased production of the parathyroid hormone (PTH) from the parathyroid glands. This can stem from abnormal secretion of the hormone as seen in primary and tertiary hyperparathyroidism. It can also be caused by defective homeostasis of the calcium metabolism, which can stimulate the production of PTH as in secondary hyperparathyroidism. The third most common endocrine disorder is primary hyperparathyroidism (PHPT), with its incidence being the highest among postmenopausal women. Seventy to eighty percent are asymptomatic, and the symptoms are related to chronic hypercalcemia rather than the elevated hormone levels. In the symptomatic group, nephrolithiasis is the most common followed by osteoporosis and increased fracture risk. With the advent of new diagnostic modalities, the severe presentation of the disease has decreased. Surgical excision of the gland(s) is a modality of choice for PHPT. Medical management is done using bisphosphonates, hormone replacement therapy, and calcimimetics and is usually required for mild disease. Secondary hyperparathyroidism occurs when the body tries to compensate for the low levels of ionized calcium by overproduction of the hormone. In the older population, vitamin D deficiency is a common cause of secondary hyperparathyroidism. Another cause is chronic kidney disease (CKD); these patients present with bone disease termed as osteodystrophy. It is also associated with cardiovascular disease and increased mortality. Treatment of secondary hyperparathyroidism is primarily medical using vitamin D supplements and calcium-based phosphate binders and calcimimetics. Dialysis is used for the management of acute nature. Tertiary hyperparathyroidism is usually a result of long-standing secondary hyperparathyroidism with autonomous parathyroid production. It can also occur with a few genetic diseases. Total parathyroid gland removal with autotransplantation in the forearm is the preferred management.

PDF Share
  1. Fraser WD. Hyperparathyroidism. Lancet 2009;374(9684):145–158. DOI: 10.1016/S0140-6736(09)60507-9.
  2. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005;42(1):35–70. DOI: 10.1080/10408360590886606.
  3. Cope O. The story of hyperparathyroidism at the Massachusetts General Hospital. New Engl J Med 1966;274(21):1174–1182. DOI: 10.1056/NEJM196605262742105.
  4. Avioli LV. Stones, bones, abdominal groans, psychic moans, and hypertones. Cardiovasc Med 1978;3(8):835.
  5. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Mineral Res 2006;21(1):171–177. DOI: 10.1359/JBMR.050910.
  6. Press DM, Siperstein AE, Berber E, et al. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery 2013;154(6):1232–1238. DOI: 10.1016/j.surg.2013.06.051.
  7. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98(3):1122–1129. DOI: 10.1210/jc.2012-4022.
  8. Lundgren E, Rastad J, Thrufjell E, et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287–294. DOI: 10.1016/s0039-6060(97)90357-3.
  9. Rao SD, Frame B, Miller MJ, et al. Hyperparathyroidism following head and neck irradiation. Arch Intern Med 1980;140(2):205–207. PMID: 7352815.
  10. Bendz H, Sjödin I, Toss G, et al. Hyperparathyroidism and long‐term lithium therapy–a cross‐sectional study and the effect of lithium withdrawal. J Intern Med 1996;240(6):357–365. DOI: 10.1046/j.1365-2796.1996.28864000.x.
  11. Thakker RV. Genetics of parathyroid tumours. J Intern Med 2016;280(6):574–583. DOI: 10.1111/joim.12523.
  12. Guan B, Welch JM, Sapp JC, et al. GCM2-activating mutations in familial isolated hyperparathyroidism. Am J Hum Genet 2016;99(5):1034–1044. DOI: 10.1016/j.ajhg.2016.08.018.
  13. Brown EM. Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab 2013;27(3):333–343. DOI: 10.1016/j.beem.2013.02.006.
  14. Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic. J Am Med Assoc 1934;102(16):1276–1287. DOI: 10.1001/jama.1934.02750160010003.
  15. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New Engl J Med 1999;341(17):1249–1255. DOI: 10.1056/NEJM199910213411701.
  16. Mallette LE, Bilezikian JP, Heath DA, et al. Primary hyperparathyroidism: clinical and biochemical features. Medicine 1974;53(2):127–146. PMID: 4361513.
  17. Malabu UH, Founda MA. Primary hyperparathyroidism in Saudi Arabia: a review of 46 cases. Med J Malaysia 2007;62(5):394–397. PMID: 18705474.
  18. Paruk IM, Esterhuizen TM, Maharaj S, et al. Characteristics, management and outcome of primary hyperparathyroidism in South Africa: a single-centre experience. Postgrad Med J 2013;89(1057):626–631. DOI: 10.1136/postgradmedj-2012-131707.
  19. Shah VN, Bhadada SK, Bhansali A, et al. Changes in clinical & biochemical presentations of primary hyperparathyroidism in India over a period of 20 years. Indian J Med Res 2014;139(5):694. PMID: 25027078.
  20. Arya AK, Kumari P, Bhadada SK, et al. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab 2021;39(2):253–259. DOI: 10.1007/s00774-020-01142-w.
  21. Viccica G, Cetani F, Vignali E, et al. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine 2017;55(1):256–265. DOI: 10.1007/s12020-016-0931-8.
  22. Walker MD, Cong E, Lee JA, et al. Vitamin D in primary hyperpar-athyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab 2015;100(9):3443–3451. DOI: 10.1210/jc.2015-2022.
  23. Cipriani C, Biamonte F, Costa AG, et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 2015;100(4):1309–1315. DOI: 10.1210/jc.2014-3708.
  24. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989;4(3):283–291. DOI: 10.1002/jbmr.5650040302.
  25. Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990;70(4):930–938. DOI: 10.1210/jcem-70-4-930.
  26. Khosla S, Melton III LJ, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population‐based study. J Bone Miner Res 1999;14(10):1700–1707. DOI: 10.1359/jbmr.1999.14.10.1700.
  27. Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94(7):2306–2312. DOI: 10.1210/jc.2008-2006.
  28. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol 2008;69(1):1–9. DOI: 10.1111/j.1365-2265.2007.03162.x.
  29. De Geronimo S, Romagnoli E, Diacinti D, et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol 2006;155(3):415–420. DOI: 10.1530/eje.1.02225.
  30. Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 2013;28(5):1029–1040. DOI: 10.1002/jbmr.1841.
  31. Walker MD, Saeed I, Lee JA, et al. Effect of concomitant vitamin D deficiency or insufficiency on lumbar spine volumetric bone mineral density and trabecular bone score in primary hyperparathyroidism. Osteoporosis Int 2016;27(10):3063–3071. DOI: 10.1007/s00198-016-3637-0.
  32. Hansen S, Hauge EM, Rasmussen L, et al. Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one‐year prospective controlled study using high‐resolution peripheral quantitative computed tomography. J Bone Miner Res 2012;27(5):1150–1158. DOI: 10.1002/jbmr.1540.
  33. Nordenström E, Westerdahl J, Lindergård B, et al. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg 2002;26(12):1463–1467. DOI: 10.1007/s00268-002-6433-2.
  34. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99(10):3561–3569. DOI: 10.1210/jc.2014-1413.
  35. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011;96(8):2377–2385. DOI: 10.1210/jc.2011-0569.
  36. Cassibba S, Pellegrino M, Gianotti L, et al. Silent renal stones in primary hyperparathyroidism: prevalence and clinical features. Endocr Pract 2014;20(11):1137–1142. DOI: 10.4158/EP14074.OR.
  37. Odvina CV, Sakhaee K, Heller HJ, et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol Res 2007;35(3):123–128. DOI: 10.1007/s00240-007-0096-2.
  38. Berger AD, Wu W, Eisner BH, et al. Patients with primary hyperparathyroidism—why do some form stones? J Urol 2009;181(5):2141–2145. DOI: 10.1016/j.juro.2009.01.028.
  39. Khaleeli AA, Johnson JN, Taylor WH. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev 2007;23(1):43–48. DOI: 10.1002/dmrr.637.
  40. Walker MD, Nickolas T, Kepley A, et al. Predictors of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab 2014;99(5):1885–1892. DOI: 10.1210/jc.2013-4192.
  41. Tassone F, Gianotti L, Emmolo I, et al. Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94(11):4458–4461. DOI: 10.1210/jc.2009-0587.
  42. Rao DS, Wilson RJ, Kleerekoper M, et al. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988;67(6):1294–1298. DOI: 10.1210/jcem-67-6-1294.
  43. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007;92(8):3114–3121. DOI: 10.1210/jc.2007-0219.
  44. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92(5):1687–1692. DOI: 10.1210/jc.2006-1836.
  45. Ogino KA, Burkhoff DA, Bilezikian JP. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 1995;136(7):3024–3030. DOI: 10.1210/endo.136.7.7789328.
  46. Collip JB, Clark EP. Further studies on the physiological action of a parathyroid hormone. J Biol Chem 1925;64(2):485–507.
  47. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94(10):3849–3856. DOI: 10.1210/jc.2009-1086.
  48. Talpos GB, Bone III HG, Kleerekoper M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 2000;128(6):1013–1021. DOI: 10.1067/msy.2000.110844.
  49. Nilsson IL, Åberg J, Rastad J, et al. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999;126(6):1049–1055. DOI: 10.1067/msy.2099.101422.
  50. Lumachi F, Ermani M, Frego M, et al. Intima-media thickness measurement of the carotid artery in patients with primary hyperparathyroidism. A prospective case-control study and long-term follow-up. In vivo 2006;20(6B):887–890. PMID: 17203784.
  51. Rosa J, Raska I, Wichterle D, et al. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res 2011;34(3):296–300. DOI: 10.1038/hr.2010.232.
  52. Schillaci G, Pucci G, Pirro M, et al. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 2011;218(1):96–101. DOI: 10.1016/j.atherosclerosis.2011.05.010.
  53. Rubin MR, Maurer MS, McMahon DJ, et al. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90(6):3326–3330. DOI: 10.1210/jc.2004-1400.
  54. Walker MD, Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Invest 2008;31(10):925–931. DOI: 10.1007/BF03346443.
  55. Iwata S, Walker MD, Di Tullio MR, et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2012;97(1):132–137. DOI: 10.1210/jc.2011-2107.
  56. Walker MD, Rundek T, Homma S, et al. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol/European Federation of Endocrine Societies 2012;167(2):277. DOI: 10.1530/EJE-12-0124.
  57. Vestergaard P, Mollerup CL, Frøkjær VG, et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003;27(2):216–222. DOI: 10.1007/s00268-002-6541-z.
  58. Streeten EA, Munir K, Hines S, et al. Coronary artery calcification in patients with primary hyperparathyroidism in comparison with control subjects from the multi-ethnic study of atherosclerosis. Endocr Pract 2008;14(2):155–161. DOI: 10.4158/EP.14.2.155.
  59. Kepez A, Harmanci A, Hazirolan T, et al. Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients. Int J Cardiovasc Imaging 2009;25(2):187–193. DOI: 10.1007/s10554-008-9369-2.
  60. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998;104(2):115–122. DOI: 10.1016/s0002-9343(97)00270-2.
  61. Ragno A, Pepe J, Badiali D, et al. Chronic constipation in hypercalcemic patients with primary hyperparathyroidism. Eur Rev Med Pharmacol Sci 2012;16(7):884–889. PMID: 22953636.
  62. Pepe J, Badiali D, Biviano I, et al. The effect of parathyroidectomy on chronic constipation in patients affected by primary hyperparathyroidism. J Bone Miner Metab 2013;31(6):690–694. DOI: 10.1007/s00774-013-0453-x.
  63. Ludvigsson JF, Kämpe O, Lebwohl B, et al. Primary hyperparathyroidism and celiac disease: a population-based cohort study. J Clin Endocrinol Metab 2012;97(3):897–904. DOI: 10.1210/jc.2011-2639.
  64. Shah VN, Shah CS, Bhadada SK, et al. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25 (OH) D, calcium and PTH levels: a meta‐analysis and review of literature. Clin Endocrinol 2014;80(6):797–803. DOI: 10.1111/cen.12398.
  65. Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 2014;99(3):1072–1080. DOI: 10.1210/jc.2013-3978.
  66. Walker MD, Cong E, Lee JA, et al. Low vitamin D levels have become less common in primary hyperparathyroidism. Osteoporosis Int 2015;26(12):2837–2843. DOI: 10.1007/s00198-015-3199-6.
  67. Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013;98(7):2734–2741. DOI: 10.1210/jc.2013-1300.
  68. Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92(8):3001–3005. DOI: 10.1210/jc.2006-2802.
  69. Tuna MM, Çalışkan M, Ünal M, et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 2016;34(3):331–335. DOI: 10.1007/s00774-015-0673-3.
  70. Koumakis E, Souberbielle JC, Sarfati E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98(8):3213–3220. DOI: 10.1210/jc.2013-1518.
  71. Maruani G, Hertig A, Paillard M, et al. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88(10):4641–4648. DOI: 10.1210/jc.2002-021404.
  72. Rejnmark L, Amstrup AK, Mollerup CL, et al. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab 2013;98(1):87–96. DOI: 10.1210/jc.2012-2499.
  73. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94(2):340–350. DOI: 10.1210/jc.2008-1758.
  74. D’Amour P, Brossard JH, Rousseau L, et al. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH (1–84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49(12):2037–2044. DOI: 10.1373/clinchem.2003.021592.
  75. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016;151(10):959–968. DOI: 10.1001/jamasurg.2016.2310.
  76. Rao DS, Phillips ER, Divine GW, et al. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004;89(11):5415–5422. DOI: 10.1210/jc.2004-0028.
  77. Brown EM. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 1991;71(2):371–411. DOI: 10.1152/physrev.1991.71.2.371.
  78. Tanaka Y, DeLuca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 1973;154(2):566–574. DOI: 10.1016/0003-9861(73)90010-6.
  79. Sommer S, Berndt T, Craig T, et al. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 2007;103(3–5):497–503. DOI: 10.1016/j.jsbmb.2006.11.010.
  80. Messa P, Alfieri C, Rastaldi MP. Recent insights into vitamin D and its receptor. J Nephrol 2011;24:S30–S37. DOI: 10.5301/JN.2011.7767.
  81. Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51(1):328–336. DOI: 10.1038/ki.1997.41.
  82. Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease: part IV of IV parts: the state of the bones in uremic hyperparathyroidism—the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis. Metabolism 1976;25(10):1157–1188. DOI: 10.1016/0026-0495(76)90024-x.
  83. Zhang Q, Qiu J, Li H, et al. Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD. J Am Soc Nephrol 2011;22(4):664–672. DOI: 10.1681/ASN.2010060594.
  84. Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 2014;85(1):166–173. DOI: 10.1038/ki.2013.279.
  85. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 2011;58(14):1433–1441. DOI: 10.1016/j.jacc.2011.03.069.
  86. Selamet U, Tighiouart H, Sarnak MJ, et al. Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3–5: the modification of diet in renal disease study. Kidney Int 2016;89(1):176–184. DOI: 10.1038/ki.2015.284.
  87. Messa P, Alfieri CM. Secondary and tertiary hyperparathyroidism. Parathyr Dis 2019;51:91–108.
  88. Naveh-Many T, Marx R, Keshet E, et al. Regulation of 1, 25-dihydroxyvitamin D3 receptor gene expression by 1, 25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990;86(6):1968–1975. DOI: 10.1172/JCI114931.
  89. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci 1985;82(12):4270–4273. DOI: 10.1073/pnas.82.12.4270.
  90. Mäkitie O, Kooh SW, Sochett E. Prolonged high‐dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X‐linked hypophosphatemic rickets. Clin Endocrinol 2003;58(2):163–168. DOI: 10.1046/j.1365-2265.2003.01685.x.
  91. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF‐23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19(3):429–435. DOI: 10.1359/JBMR.0301264.
  92. Bleskestad IH, Bergrem H, Leivestad T, et al. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant 2011;25(5):E566–E570. DOI: 10.1111/j.1399-0012.2011.01515.x.
  93. Gilat H, Feinmesser R, Vinkler Y, et al. Clinical and operative management of persistent hyperparathyroidism after renal transplantation: a single‐center experience. Head Neck 2007;29(11):996–1001. DOI: 10.1002/hed.20628.
  94. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):S1–S30. DOI: 10.1038/ki.2009.188.
  95. Schlosser K, Endres N, Celik I, et al. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J Surg 2007;31(10):1947–1953. DOI: 10.1007/s00268-007-9187-z.
  96. Hsieh TM, Sun CK, Chen YT, et al. Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am Surg 2012;78(5):600–606. PMID: 22546135.
  97. Sadideen HM, Taylor JD, Goldsmith DJ. Total parathyroidectomy without autotransplantation after renal transplantation for tertiary hyperparathyroidism: long-term follow-up. Int Urol Nephrol 2012;44(1):275–281. DOI: 10.1007/s11255-011-0069-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.